Multimodal selenium nanoshell-capped Au@mSiO2 nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer
Source abstract
Abstract
Multimodal therapeutic agents based on novel nanomaterials for multidrug resistance have attracted increasing attention in cancer therapy. In this study, we describe the construction of a programmed mesoporous silica-capped gold nanorod covered with nano-selenium overcoat (Se@Au@mSiO 2 ) nanoparticles as a multifunctional nanoplatform to incorporate materials with specific chemotherapeutic, chemoprevention, and photoablation/hyperthermia functions that collectively contribute to enhance anticancer efficacy in multidrug-resistant breast cancer. The triplecombination-based nanosized Se@Au@mSiO 2 /DOX effectively accumulates in the tumor and the release of the therapeutic cargo could be remotely manipulated by mild near-infrared (NIR) irradiation. Se@Au@mSiO 2 /DOX notably enhances the cell killing effect through induction of cell apoptosis. In addition, Se@Au@mSiO 2 /DOX inhibits tumor cell growth through cell cycle arrest and induction of apoptosis via suppression of the Src/FAK/AKT signaling pathways. Synergistic Se-photothermal-chemotherapy combination exhibits significant tumor growth suppression and delayed tumor progression in vivo. Immunohistochemistry analysis shows elevated numbers of caspase-3 and PARPimmunolabeled cells and decreased Ki-67 + and CD31 + cancer cells in the tumor mass. No noticeable signs of organ damage or toxicity are observed after treatment with Se@Au@mSiO 2 /DOX (NIR+), which is further supported by hematology and biochemical analyses. Thus, Se@Au@mSiO 2 /DOX has potential for the clinical treatment of metastatic breast cancers with little or no adverse effects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Selenium in Biological Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).10.1002/ijc.25516 ↗
2. Yager, P. et al. Microfluidic diagnostic technologies for global public health. Nature 442, 412–418 (2006).10.1038/nature05064 ↗
3. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007).10.1038/nnano.2007.387 ↗
4. Du, Q. et al. Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. Oncol. Rep. 29, 1851–1858 (2013).10.3892/or.2013.2310 ↗
5. Qiu, L. et al. A cell-targeted, size-photocontrollable, nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy. Nano Lett. 15, 457–463 (2014).10.1021/nl503777s ↗
6. Rayman, M. P. The importance of selenium to human health. Lancet 356, 233–241 (2000).10.1016/S0140-6736(00)02490-9 ↗
7. Hu, H. et al. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and surviving. Clin. Cancer Res. 14, 1150–1158 (2008).10.1158/1078-0432.CCR-07-4037 ↗
8. Sun, D. et al. The effects of luminescent ruthenium (II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials 34, 171–180 (2013).10.1016/j.biomaterials.2012.09.031 ↗
9. Liu, W. et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano 6, 6578–6591 (2012).10.1021/nn202452c ↗
10. Fakih, M., Cao, S., Durrani, F. A. & Rustum, Y. M. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin. Colorectal Cancer 5, 132–135 (2005).10.3816/CCC.2005.n.026 ↗
11. Zhang, J., Wang, X. & Xu, T. Elemental selenium at nano size (Nano-Se) as a potential chemopreventive agent with reduced risk of selenium toxicity: comparison with se-methylselenocysteine in mice. Toxicol. Sci. 101, 22–31 (2008).10.1093/toxsci/kfm221 ↗
12. Ramasamy, T. et al. Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review. J Control. Release 258, 226–253 (2017).10.1016/j.jconrel.2017.04.043 ↗
13. You, J. et al. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 72, 4777–4786 (2012).10.1158/0008-5472.CAN-12-1003 ↗
14. Hyvärinen, M. Ultraviolet Light Protection and Weathering Properties of Wood-polypropylene Composites. Doctoral Dissertation, Acta Universitatis Lappeenrantaensis (2014).
15. Li, X., Takashima, M., Yuba, E., Harada, A. & Kono, K. PEGylated PAMAM dendrimer–doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy. Biomaterials 35, 6576–6584 (2014).10.1016/j.biomaterials.2014.04.043 ↗
16. Huang, X., Jain, P. K., El-Sayed, I. H. & El-Sayed, M. A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 23, 217–228 (2008).10.1007/s10103-007-0470-x ↗
17. Dykman, L. & Khlebtsov, N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev. 41, 2256–2282 (2012).10.1039/C1CS15166E ↗
18. Hauck, T. S., Jennings, T. L., Yatsenko, T., Kumaradas, J. C. & Chan, W. C. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv. Mater. 20, 3832–3838 (2008).10.1002/adma.200800921 ↗
19. You, J., Zhang, G. & Li, C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano 4, 1033–1041 (2010).10.1021/nn901181c ↗
20. Shen, S. et al. Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with near-infrared radiation. Biomaterials 34, 3150–3158 (2013).10.1016/j.biomaterials.2013.01.051 ↗
21. DeLisser, H. et al. Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc. Natl Acad. Sci. 107, 18616–18621 (2010).10.1073/pnas.1004654107 ↗
22. Awasthi, N., Zhang, C., Ruan, W., Schwarz, M. A. & Schwarz, R. E. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol. Cancer Ther. 11, 2644–2653 (2012).10.1158/1535-7163.MCT-12-0447 ↗
23. Sau, T. K. & Murphy, C. J. Seeded high yield synthesis of short Au nanorods in aqueous solution. Langmuir 20, 6414–6420 (2004).10.1021/la049463z ↗
24. Ramasamy, T. et al. pH sensitive polyelectrolyte complex micelles for highly effective combination chemotherapy. J. Mater. Chem. B 2, 6324–6333 (2014).10.1039/C4TB00867G ↗
25. Ramasamy, T. et al. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 10, 5116–5127 (2014).10.1016/j.actbio.2014.08.021 ↗
26. Ramasamy, T. et al. Layer-by-layer coated lipid–polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr. Polym. 102, 653–661 (2014).10.1016/j.carbpol.2013.11.009 ↗
27. Ramasamy, T. et al. Chitosan-based polyelectrolyte complexes as potential nanoparticulate carriers: physicochemical and biological characterization. Pharm. Res. 31, 1302–1314 (2014).10.1007/s11095-013-1251-9 ↗
28. Zhang, Z., Wang, J. & Chen, C. Near‐infrared light‐mediated nanoplatforms for cancer thermo‐chemotherapy and optical imaging. Adv. Mater. 25, 3869–3880 (2013).10.1002/adma.201301890 ↗
29. Ramasamy, T. et al. Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan. Chem. Commun. 51, 5758–5761 (2015).10.1039/C5CC00482A ↗
30. Ramasamy, T., Kim, J., Choi, H. G., Yong, C. S. & Kim, J. O. Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J. Biomed. Nanotechnol. 10, 1304–1312 (2014).10.1166/jbn.2014.1821 ↗
31. Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 151, 220–228 (2011).10.1016/j.jconrel.2010.11.004 ↗
32. Tran, T. H. et al. Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells. Int. J. Nanomed. 10, 5249 (2015).
33. Ramasamy, T. et al. Engineering of cell microenvironment-responsive polypeptide nanovehicle co-encapsulating a synergistic combination of small molecules for effective chemotherapy in solid tumors. Acta Biomater. 48, 131–143 (2017).10.1016/j.actbio.2016.10.034 ↗
34. Ramasamy, T. et al. Cationic drug-based self-assembled polyelectrolyte complex micelles: Physicochemical, pharmacokinetic, and anticancer activity analysis. Colloids Surf. B: Biointerfaces 146, 152–160 (2016).10.1016/j.colsurfb.2016.06.004 ↗
35. Shrestha, R., Elsabahy, M., Florez-Malaver, S., Samarajeewa, S. & Wooley, K. L. Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities. Biomaterials 33, 8557–8568 (2012).10.1016/j.biomaterials.2012.07.054 ↗
36. Meng, H. et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5, 4131–4144 (2011).10.1021/nn200809t ↗
37. Suematsu, N., Hosoda, M. & Fujimori, K. Protective effects of quercetin against hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Neurosci. Lett. 504, 223–227 (2011).10.1016/j.neulet.2011.09.028 ↗
38. Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013).10.1038/nrd4002 ↗
39. Broude, E. et al. p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation. Oncogene 26, 6954–6958 (2007).10.1038/sj.onc.1210516 ↗
40. Sundaramoorthy, P. et al. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells. Acta Biomater. 42, 220–231 (2016).10.1016/j.actbio.2016.07.006 ↗
41. Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J. & Lukas, J. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842–847 (2001).10.1038/35071124 ↗
42. Ruttala, H. B. et al. Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy. Oncotarget 8, 14925 (2017).10.18632/oncotarget.14742 ↗
43. Ruttala, H. B. et al. Multiple polysaccharide-drug complex-loaded liposomes: A unique strategy in drug loading and cancer targeting. Carbohydr. Polym. 176, 57–66 (2017).10.1016/j.carbpol.2017.05.062 ↗
44. Fang, E. F. et al. Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis. PLoS ONE 7, e41592 (2012).10.1371/journal.pone.0041592 ↗
45. Qin, Y. et al. Cardamonin exerts potent activity against multiple myeloma through blockade of NF-κB pathway in vitro. Leuk. Res. 36, 514–520 (2012).10.1016/j.leukres.2011.11.014 ↗
46. Ramasamy, T. et al. Polypeptide-based micelles for delivery of irinotecan: physicochemical and in vivo characterization. Pharm. Res. 32, 1947–1956 (2015).10.1007/s11095-014-1588-8 ↗